When you're diagnosed with melanoma, one of the big questions is whether the cancer has spread to the nearby lymph nodes. A new analysis of data from over 40,000 adults with melanoma suggests that a procedure called sentinel node biopsy—which checks those first lymph nodes—is linked to better outcomes. People who had this procedure had a significantly lower risk of dying from melanoma and a lower risk of their cancer recurring compared to those who did not have it. The analysis combined results from 13 studies, and the researchers note their findings line up with the only major trial on this topic. However, it's important to understand what this data can and can't tell us. The benefit for survival was clear at the five-year mark, but when looking at a ten-year timeframe, the link was no longer statistically significant. Also, most of the studies included were observational, meaning they looked back at what happened to people rather than randomly assigning them to get the procedure or not. The researchers argue the evidence points to a real benefit, but they didn't report on the safety or side effects of the biopsy itself in this review.
Does checking lymph nodes help people with melanoma live longer?
Photo by National Cancer Institute / Unsplash
What this means for you:
Checking lymph nodes in melanoma is linked to better survival and lower recurrence risk. More on Melanoma
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types.
· May 1, 2026
Narrative review discusses MicroRNAs in melanoma without reported outcomes or safety data A review explores how MicroRNAs might relate to Melanoma
Frontiers · May 1, 2026
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments Fertility Drugs Linked to Slight Rise in Melanoma Risk
· Apr 29, 2026
Pathologic features predict rapid recurrence in T1 melanoma patients across 14 sites. Why Thin Melanomas Kill Older Adults
medRxiv · Apr 10, 2026